Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.38 |
| ▸ | DRD3 | P35462 | 8/20 | 0.38 |
| ▸ | DRD4 | P21917 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093471 | 0.74 | CYP2A6 (0.42) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5237404 | 0.72 | HRH3 (0.53) | KDM1AHRH3CHRM3 | |
| SCHEMBL2096626 | 0.71 | CYP2A6 (0.39) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1001038 | 0.69 | USP2 (0.71) | USP2HRH2HRH1HRH3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7388875 | 0.68 | CA1 (0.36) | DRD2DRD3DRD4SLC6A4SLC6A2 | |
| SCHEMBL14432506 | 0.68 | SOS1 (0.58) | KDM1AUSP2DRD2DRD3HRH2 | |
| Hydrochloric Acid SCHEMBL19457676 | 0.67 | USP2 (0.69) | USP2HRH2HRH1HRH3CHRM3 | |
| SCHEMBL13995933 | 0.67 | USP2 (0.69) | USP2HRH2HRH1HRH3CHRM3 | |
| SCHEMBL38659199 | 0.67 | CHRM3 (0.60) | USP2DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL639856 | 0.67 | CHRM3 (0.60) | USP2DRD2DRD3DRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | KDM1A 1919/4885USP2 3275/4885DRD2 43/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | KDM1A 3412/4885USP2 3899/4885DRD2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.